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Introduction
The accurate staging of lung cancer is an essential diagnostic 
step that influences the choice of neoadjuvant and adjuvant 
therapy and the intraoperative surgical strategy. The TNM 
system describing the anatomical extent of malignant 
tumors is one of the most widely adopted cancer staging 
systems, and is used by most medical facilities as their main 
method for cancer reporting.
The initial TNM staging system for lung cancer was 
first adopted by the American Joint Commission on Cancer 
(AJCC) in 1973 and by the Union for International Cancer 
Control (UICC) in 1974 (1). The current seventh edition 
of the TNM system for lung cancer was based on an 
international database of 81,495 patients collected between 
1990 and 2000 by the International Association of the Study 
of Lung Cancer (IASLC) (2). The changes proposed by the 
IASLC were fully approved by both the UICC and the AJCC 
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and are reflected in the current seventh edition of the TNM 
staging system. However, despite the vastness of the IASLC 
database and various external validations by independent 
groups (3,4), not all descriptors of the T component could 
be validated because many of the contributing databases had 
not been designed to analyze the TNM system. The resulting 
lack of detailed data necessitated the collection of new data.
The new eighth edition of the TNM system is the 
product of an extensive initiative by the IASLC, involving 
a database of 94,708 patients, although it has not yet been 
externally validated (5). Here, we describe the first study 
attempting to validate the revisions of the T descriptors in 
the forthcoming eighth edition of the TNM system for lung 
cancer. We reviewed the survival characteristics of patients 
and compared the predictive abilities of the newly proposed 
T descriptors for non-small cell lung cancer (NSCLC).
Methods
Patients
A total of 2,133 consecutive patients who underwent 
surgery for NSCLC between January 1999 and December 
2012 at our institute were analyzed. Of these, patients for 
whom an incomplete resection (R1 or R2 resection) could 
be performed, who underwent preoperative chemoradiation 
therapy, who died within 1 month following surgery, or 
who had a tumor with histology other than NSCLC were 
excluded. Patients who had a positive nodal status or 
distant metastasis were also excluded. When the ground 
glass opacity (GGO) lesion, which had 5 mm or more solid 
component, was detected on computed tomography (CT) 
scan, we considered a biopsy or surgical resection. If GGO 
lesion was diagnosed as pre-invasive lesion such as atypical 
adenomatous hyperplasia (AAH) and adenocarcinoma 
in situ (AIS), we observed without further definitive surgery 
and excluded from this study. Consequently, 1,316 patients 
were included in the analysis of the pathologic T category 
(Figure 1). This study was reviewed and approved by the 
Institutional Review Board at Yonsei University Health 
System, Severance Hospital (No. 4-2017-0935).
Statistical analysis
Overall survival was defined as the interval between the date 
Figure 1 Flow chart of patients in this study. NSCLC, non-small cell lung cancer.
1999–2012
Operation for NSCLC
N=2,133
N=2,119
N=2,075
N=1,350
N=1,338
pN0M0 R0
N=1,316
Exclusion criteria
Incomplete resection
N=14
Neoadjuvant treatment
N=44
Pathologic N positive
N=725
Pathologic M positive
N=12
Operative morality
N=22
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Table 1 Comparison of the T descriptors of the 7th and 8th TNM 
staging system
T component 7th edition 8th edition
Size
Tumor ≤1 cm T1a T1a
1 cm < Tumor ≤2 cm T1a T1b
2 cm < Tumor ≤3 cm T1b T1c
3 cm < Tumor ≤4 cm T2a T2a
4 cm < Tumor ≤5 cm T2a T2b
5 cm < Tumor ≤7 cm T2b T3
7 cm < Tumor T3 T4
Atelectasis/obstructive pneumonia
Partial T2 T2
Total T3 T2
Involvement in main bronchus
≥2 cm distal to the carina T2 T2
<2 cm distal to the carina T3 T2
Directly invasion to mediastinal pleura T3 Deletion
Directly invasion to diaphragm T3 T4
Separate nodule
Same lobe T3 T3
Different ipsilateral lobe T4 T4
of surgery and either the date of death from any cause or 
the last clinical visit. The Kaplan-Meier method was used 
to estimate the overall survival in the different T categories. 
The significance of differences between the survival curves 
was calculated using the log-rank test.
We used Harrell’s concordance (C)-index and Heagerty’s 
integrated area under the curve (iAUC) analysis to assess 
the discriminatory abilities of the different TNM staging 
systems (6,7). The C-index has been widely used for 
assessing predictive values in survival analysis, and has a 
value between 0.5 (no discrimination) and 1.0 (perfect 
discrimination). The estimated iAUC compares the 
predictive accuracy for time to event data using the rank 
sum test method for dependent samples when the random 
censoring assumption holds.
All reported p values were 2-sided, and a value of P<0.05 was 
considered statistically significant. SPSS 20 for windows v20.0 
(SPSS Inc., Chicago, IL, USA) and R package version 3.0.1 
(http://www.R-project.org) were used for statistical analyses.
Results
An overview of the current and proposed T category definitions 
is given in Table 1. The study cohort of 1,316 patients 
included 500 (38.0%) female and 816 (62.0%) male 
patients, with a mean age of 63.1±0.3 years. Lobectomy was 
performed in 1,131 (85.9%) patients, and 1,249 (95.0%) 
pat ients  were  patholog ica l ly  conf i rmed to  have 
adenocarcinoma or squamous cell carcinoma. The patients’ 
baseline characteristics are summarized in Table 2, and 
the distribution of cases according to seventh and newly 
proposed eighth TNM staging system is given in Table 3. 
Under the eighth TNM staging system, 771 (58.6%) 
patients were assigned to a higher pathologic stage and 
16 (1.2%) to a lower one.
The 5-year survival rate and the survival curves according 
to the T descriptors of the seventh and eighth editions 
are shown in Figure 2. In the seventh edition, the survival 
curves showed a stepwise deterioration as the pathologic 
stage increased except between T1b and T2a (P=0.874), and 
T3 and T4 (P=0.943). However, there were no significant 
survival differences between each stage based on the T stage 
criteria of the eighth edition, most notably between T1a 
and T1b (P=0.752), and T1c, T2a, and T2b (P=0.832).
Comparison of the TNM prognostic classification systems
Statistical assessment of the prognostic performance of two 
TNM staging editions using the C-index revealed a value 
of 0.681 (95% CI, 0.651–0.710) for the seventh edition, and 
0.675 (95% CI, 0.643–0.705) for the eighth edition. We 
found no significant improvement in prognostic accuracy 
between the seventh and eighth editions (Table 4).
Moreover, we calculated the AUC after surgery for each 
follow-up period. A larger iAUC indicates a better average 
predictability of time to event. The iAUC values of two 
TNM staging editions varied between 0.59 and 0.64, and 
the eighth edition also showed no relevant difference in the 
iAUC value compared with the seventh edition (Figure 3). 
The newly proposed eighth edition of the TNM staging 
system thus did not predict survival more accurately than 
the seventh edition.
Discussion
In this study, we performed a retrospective analysis in 
order to assess whether the prognostic significance of the 
newly proposed T descriptors of the eighth TNM staging 
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system in patients who underwent surgery for NSCLC was 
greater than those of the previous TNM staging systems. 
The T descriptor in the eighth edition showed narrower 
discrimination between sequential stage groups and did 
not have a better prognostic performance than the seventh 
edition. Based on these results, the newly proposed T 
descriptors in the forthcoming eighth edition of the TNM 
classification for NSCLC were not superior with respect 
to prognostic stratification amongst patients from our 
institution.
Although the current seventh TNM staging system for 
NSCLC adopted in 2010 was based on a database of more 
than 80,000 patients collected worldwide, not all descriptors 
could be validated. For the T category, only tumor size, 
additional tumor nodules, and pleural effusion could be 
analyzed reliably, necessitating the revision of the staging 
system (8). The most extensive changes proposed by IASLC 
for the eighth edition pertained to the T classification, 
with the importance of tumor size being highlighted (9). 
Moreover, invasion of the diaphragm, as an indicator 
of stage T4, was shown to be associated with a poor 
prognosis. When tumors larger than 7 cm and invasion 
of the diaphragm as stage T4 were included, there were 
statistically significant differences between T3 and T4 with 
respect to survival outcomes (9). These changes therefore 
allowed a more accurate prognosis, which could help 
better determine whether a patient is eligible for surgery. 
However, despite the advances this classification offered, 
we found no significant differences between the survival 
rate of patients with T1a and T1b disease, or between those 
with T1c, T2a and T2b disease. Furthermore, although 
the C-index and iAUC analyses indicated no statistically 
significant differences in the prediction of survival between 
the seventh and eighth editions, the increasing worse 
Table 2 Patients’ characteristics (N=1,316)
Variables No. (%)
Age (mean, SD) 63.1±0.3
Sex
Male 816 (62.0)
Female 500 (38.0)
Tumor histology
Squamous cell carcinoma 385 (29.3)
Adenocarcinoma 864 (65.7)
Large cell carcinoma 44 (3.3)
Adenosquamous 19 (1.4)
Others 4 (0.3)
Tumor location
RUL 387 (29.4)
RML 117 (8.9)
RLL 297 (22.6)
LUL 308 (23.4)
LLL 207 (15.7)
Tumor differentiation
Well 151 (11.5)
Moderate 432 (32.8)
Poor 280 (21.3)
Not assessed 453 (34.4)
Type of resection
Pneumonectomy 75 (5.7)
Bilobectomy 74 (5.6)
Lobectomy 1131 (85.9)
Segmentectomy 6 (0.5)
Wedge resection 30 (2.3)
RUL, right upper lobe; RML, right middle lobe; RLL, right lower 
lobe; LUL, left upper lobe; LLL, left lower lobe; SD, standard 
deviation.
Table 3 Comparison of patients’ distribution between the 7th and 8th TNM staging system
7th edition
8th edition
T1a T1b T1c T2a T2b T3 T4 Total [n (%)]
T1a 84 274 – – – – – 358 (27.2)
T1b – – 238 – – – – 238 (18.1)
T2a – – – 375 111 – – 486 (37.0)
T2b – – – – – 84 – 84 (6.3)
T3 – 1 6 5 4 52 64 132 (10.0)
T4 – – – – – – 18 18 (1.4)
Total n (%) 84 (6.4) 275 (20.9) 244 (18.5) 380 (28.9) 115 (8.7) 136 (10.3) 82 (6.3) 1,316 [100]
TNM, tumor, node and metastasis.
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survival that occurred with increasing pathologic T stage 
was less apparent in the eighth edition.
We hypothesized that the discrepancies in the results 
of the analysis of different series was due to the diversity 
and origins of the database. Our study populations were 
different from those of the IASLC database. Although the 
new IASLC database for the eighth edition was collected 
internationally from different local databases, providing a 
wide geographic representation, the geographic distribution 
was still weighted towards Asia, especially Japan. In the 
eighth edition, cases from Asia contributed 79% of the 
clinical and pathological data to the new IASLC database, 
comparing only 12% of the total database in the current 
seventh edition (2,5). There was a predominance of early 
stages in Asia data in the eighth edition. However, in 
contrast with other Asia populations, our patients with 
sub-solid nodules such as AAH, AIS or minimally invasive 
adenocarcinoma (MIA) were not candidates for surgical 
resection and excluded from the study. This surgical 
indication contributed to a lower prevalence of early stage 
tumors and may skew the data toward more advanced 
stages in our cohort. Moreover, Rami-Porta et al. pointed 
out a number of limitations in their study (9). Much of 
the contributing database for the revision of new staging 
Table 4 Comparison of the prognostic performance of the 7th and 8th TNM staging system
Model Harrell’s C-index 95% CI Heagerty’s iAUC 95% CI
7th 0.681 0.651 to 0.710 0.637 0.611 to 0.664
8th 0.675 0.643 to 0.705 0.631 0.603 to 0.659
7th vs. 8th 0.006 −0.003 to 0.015 0.006 −0.004 to 0.018
CI, confidence interval; iAUC, integrated area under the curve; TNM, tumor, node and metastasis.
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Figure 2 Overall survival curves for patients stratified by the T descriptors based on (A) the 7th edition and (B) the 8th edition. 5Y-OS, 5-year 
overall survival.
Figure 3 Time-dependent ROC curve analysis for overall survival 
prediction. Integrated area under the curve (iAUC) of the 7th and 
8th edition was 0.637 and 0.631, respectively. AUC, area under curve; 
ROC, receiver operating characteristic. 
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had not been designed to validate the TNM classification, 
nor did it always contain all of the descriptors needed 
for analysis. In addition, the T3 and T4 subsets in the 
new IASLC database were smaller, and thus a number of 
comparisons could not be made for theses subsets and were 
not reported. 
Our study has some limitations. Several subgroups (T3 and 
T4) contained only a small number of patients, so the survival 
rates may have been misinterpreted. Additionally, the disease 
entities were different from those of the IASLC database. 
As mentioned above, our study had lower prevalence of 
early stage tumors. If we had a larger component of tumor 
including the bronchioloalveolar carcinoma, similar spectrum 
of prognostic stratification may be presented as the IASLC 
cohort. Furthermore, all the enrolled patients in this study 
had node negative status. Thus, to further assess the value 
of the eighth TNM staging system, evaluation of the nodal 
descriptors might be necessary.
In conclusion, the results of our retrospective study 
confirmed that the newly proposed T descriptors in the 
forthcoming eighth TNM staging system did not provide 
a more precise predictor of prognosis than those of the 
current seventh edition. This does not necessarily mean 
that the eighth edition is inferior with respect to prognostic 
stratification compared to the current TNM staging system. 
We believe that the external validation of the new TNM 
classification for lung cancer performed by independent 
groups is generally partial and prognosis should be based 
on local data because of different medical environments and 
populations.
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